We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

Shares of Pfizer Inc. PFE slipped 4.00% to $21.59 Thursday, on what proved to be an all-around dismal trading session for the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer Inc (NYSE:PFE) shares are moving lower Wednesday alongside several pharmaceutical giants after President Donald Trump ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Value investors rely on traditional forms of analysis on key ... now is Pfizer (PFE). PFE is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with P/E ratio ...